Actors and Networks database
The evolving field of gene and cell therapy is supported by a large community of academic, clinical, translational, regulatory and patient organisations. The Actors and Networks database maps these stakeholders in Europe and beyond, their activities, and resources they have produced.
EuroGCT has developed and compiled this database for those interested in identifying the actors involved at each stage of the pathways bringing gene and cell therapies from lab to clinic. Coming from an academic perspective, our focus is to map information that has not been mapped elsewhere. This includes documenting the various types of interconnected regulators, patient groups actively involved along the pathways, and non-profit organisations devoted to therapy development. In its first iteration, this database does not yet include commercial partners and service providers.
Additional complementary work by other organisations on GCT stakeholders mapping can be found here.
Action Duchenne
Additional information
Action Duchenne is a charity that supports families and individuals affected by Duchenne muscular dystrophy (DMD), a rare and progressive muscle-wasting condition.
Agence de la Biomédecine (ABM)
Additional information
The ABM receives applications for authorisation of embryo research, declarations of research on human embryonic stem cells and declarations of certain research on human induced pluripotent stem cells (those concerning differentiation into gametes, obtaining models of in vitro embryonic development, and the insertion of these cells into an animal embryo with the aim of transferring it to a female). It authorises the import and export of human embryonic stem cells. It issues opinions on clinical research involving its areas of competence. It is the competent authority for biovigilance.
Agence Nationale de la Recherche (National Research Agency) (ANR)
Agence nationale de sécurité du médicament et des produits de santé (ANSM)
Additional information
The ANSM ensures the safety of health products, especially medicinal products and medical devices, throughout their life cycle. It is informed of research involving humans and authorises clinical trials. The ANSM also authorises ‘cell therapy preparations’ and advanced therapy medicinal products falling within the scope of the hospital exemption, and establishments carrying out activities related to these preparations and medicines.
Agence régionale de santé (Regional Health Agencies) (ARS)
Alliance for Regenerative Medicine (ARM)
Additional information
ARM is an international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM represents the interests of 400+ members across 25 countries, including small and large companies, academic research institutions, major medical centers and patient groups.
ATMP Sweden
Additional information
ATMP Sweden is a national network for activities on Advanced Therapy Medicinal Products (ATMPs)
Austrian Federal Office for Safety in Health Care (BASG)
Additional information
BASG work as the national authority for medicines, medical devices, blood and tissue together with the Austrian Medicines and Medical Devices Agency, a business division of the Austrian Agency for Health and FoodSafety (AGES MEA).
Banque publique d’investissement (Public Investment Bank) (BPI)